Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Cardiff Oncology, Inc. (CRDF)
Price$1.34Cached quote
Net income
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $593,000 | $683,000 | $488,000 | $386,000 | $359,000 | $366,000 | $244,632 | $378,325 | $505,404 | $381,072 | $312,812 | $280,178 | $259,246 | $450,404 | $257,696 | — | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | $244,632 | −$219,132 | −$1.3M | −$1.3M | −$316,379 | $264,737 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | 100.00% | −57.92% | −258.41% | −354.12% | −101.14% | 94.49% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $35.3M | $36.9M | $32.9M | $27.1M | $17.4M | $11.2M | $11.2M | $8.2M | $7.9M | $15.0M | $10.6M | $6.7M | $3.9M | $1.9M | $910,685 | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $49.6M | $49.3M | $45.9M | $40.3M | $29.2M | $19.5M | $16.9M | $17.4M | $26.1M | $40.5M | $25.6M | $15.2M | $10.9M | $5.3M | $3.2M | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$49.0M | −$48.7M | −$45.4M | −$39.9M | −$28.9M | −$19.1M | −$16.7M | −$17.1M | −$25.6M | −$40.1M | −$25.3M | −$14.9M | −$10.7M | −$4.8M | −$3.0M | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −8,256.32% | −7,123.13% | −9,305.74% | −10,337.31% | −8,037.60% | −5,214.75% | −6,817.79% | −4,507.61% | −5,064.42% | −10,534.91% | −8,079.50% | −5,334.17% | −4,123.71% | −1,076.62% | −1,155.16% | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$48.6M | −$48.2M | −$45.0M | −$39.7M | −$28.4M | −$18.6M | −$16.2M | −$16.2M | −$24.3M | −$39.1M | −$24.9M | −$14.7M | −$10.6M | −$4.8M | −$3.0M | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA margin | −8,194.94% | −7,063.98% | −9,224.18% | −10,276.17% | −7,911.98% | −5,087.43% | −6,615.76% | −4,280.43% | −4,817.58% | −10,254.25% | −7,958.44% | −5,250.36% | −4,073.36% | −1,067.33% | −1,151.17% | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$45.9M | −$45.4M | −$41.4M | −$38.7M | −$28.3M | −$19.3M | −$16.4M | −$16.5M | −$24.9M | −$39.2M | −$27.5M | −$14.3M | −$11.8M | −$11.6M | −$2.2M | −$5.4M | −$2.5M | −$5.2M | −$4.7M | −$7.1M | −$7.8M | −$5.4M | −$383,021 | −$481,609 | −$524,224 | −$267,599 |
| Net profit margin | −7,732.04% | −6,651.68% | −8,492.01% | −10,026.94% | −7,880.50% | −5,275.14% | −6,709.74% | −4,351.07% | −4,928.09% | −10,287.75% | −8,781.98% | −5,112.99% | −4,555.88% | −2,567.91% | −868.94% | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.69 | -$0.95 | -$0.93 | -$0.89 | -$0.73 | -$1.08 | -$2.80 | -$8.26 | -$51.76 | -$93.60 | -$75.60 | -$54.72 | -$50.40 | -$64.08 | -$16.56 | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.69 | -$0.95 | -$0.93 | -$0.89 | -$0.73 | -$1.08 | -$2.80 | -$8.26 | -$51.76 | -$98.64 | -$87.12 | -$63.36 | -$50.40 | -$64.08 | -$16.56 | — | — | — | — | — | — | — | — | — | — | — |
Owners
Reported shareholders
4.52%of listed shares
Laurion Capital Management LP3.1M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Laurion Capital Management LP | 4.52%3.1M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.23%2.9M shares |
Pfizer Inc | 3.52%2.41M shares |
PACE GARY W | ≈1.98%1.36M shares |
FRANKLIN RESOURCES INC | 1.76%1.21M shares |
BlackRock, Inc. | 1.42%972.87K shares |
BLAIR WILLIAM & CO/IL | 1.33%912.51K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.20%820.06K shares |
UBS Group AG | 0.93%638.7K shares |
JANE STREET GROUP, LLC | 0.89%607.9K shares |
VANGUARD FIDUCIARY TRUST CO | 0.60%410.6K shares |
AQR CAPITAL MANAGEMENT LLC | 0.51%346.35K shares |
STATE STREET CORP | 0.48%331.4K shares |
HRT FINANCIAL LP | 0.40%272.79K shares |
FLPUTNAM INVESTMENT MANAGEMENT CO | 0.36%247.47K shares |
MORGAN STANLEY | 0.36%246.1K shares |
BNP PARIBAS FINANCIAL MARKETS | 0.33%228.46K shares |
X-Square Capital, LLC | 0.30%205.7K shares |
GSA CAPITAL PARTNERS LLP | 0.25%173.27K shares |
MARSHALL WACE, LLP | 0.24%162.21K shares |
Percentages use 68.5M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 18, 2026Form 4 | Mohindru ManiChief Executive Officer | BuyCommon Stock | 24.7K | $1.21 | $29.9K | 24.7K |
| Jun 18, 2026Form 4 | PACE GARY WDirector | BuyCommon Stock | 30.0K | $1.22 | $36.6K | 1.36M |
| Jul 30, 2025Form 4 | PACE GARY WDirector | BuyCommon Stock · indirect | 15.0K | $2.45 | $36.8K | 1.35M |
| Jul 30, 2025Form 4 | PACE GARY WDirector | BuyCommon Stock | 275.0K | $2.45 | $673.8K | 1.33M |
| Dec 18, 2024Form 4 | Levine James E.Chief Financial Officer | BuyCommon Stock · indirect | 2.4K | $5.00 | $12.0K | 67.7K |